A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies.

Trial Profile

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2013

At a glance

  • Drugs TAK 901 (Primary)
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Haematological malignancies; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Polycythaemia vera; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 23 Jan 2013 Planned end date changed from 1 Nov 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 27 Apr 2012 Planned End Date changed from 1 May 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 11 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top